abstract |
Compound capable of modulating, at least partially, the interaction between the PAP1 protein, or a homolog thereof, and parkin. Also disclosed are pharmaceutical compounds comprising at least one such compound and the use of such a compound in the manufacture of a medicament for use in treating neurodegenerative pathologies. |